1. Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest www.briantempest.com Shanghai, China 18 November 2011

2. Hale & Tempest Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. Brian has worked in the Pharmaceutical Industry for the last 40 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world. He is now Independent Chairman of Religare Capital Markets PLC and Non Executive Director of SRL the largest Indian Diagnostic Company. Brian is an international advisor to MAPE, India and the United Nations (UNCTAD) in addition to being a member of the SCRIP Global awards panel he is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com. Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School which ranks 4 th in the UK He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest

3. Hale & Tempest Indian Pharma around the world Source: Factset, Religare

4. Hale & Tempest The Ranbaxy Experience Exports % share of Sales Source : Ranbaxy Company Data, Credit Suisse, 12 th September 2006

5. Hale & Tempest Ranbaxy Sales Today Source: Normura, Company Data

6. Hale & Tempest Global Sales of all Indian Pharma US$b Source: IBEF, Religare

7. Hale & Tempest Emerging World Share of Pharma Source EIU, OECD, WHO, IMS, Roland Berger

8. Hale & Tempest WHO Pre Qualified Products

9. Hale & Tempest Indian Players by Sector Source: Religare

10. Hale & Tempest Indian Companies by Market Share Source: Religare

11. Hale & Tempest India % share of US API Generic Filings Source: IBEF, Religare

12. Hale & Tempest India % share of US API Generic Filings Source: JM Financials 17 August 2011

13. Hale & Tempest China % share of US API Generics Filings Source: JM Financials 17 August 2011

14. Hale & Tempest DF Exports from India $b Source: Religare, IBEF

15. Hale & Tempest India % Share of US DF Generics Market Source: Religare, IBEF

16. Hale & Tempest Number of USA Para IV Filings Source: Thomson Reuters 31 March 2011

17. Hale & Tempest Indian Generic FDA ANDA Approvals

18. Hale & Tempest Future New Product Pipeline in USA Source: JM Financials 18 August 2011

19. Hale & Tempest Niche Technology Source: MAPE

20. Hale & Tempest Top 25 Global Generic Companies Source: Generics Bulletin 10 June 2011

21. Hale & Tempest Next 24 Global Generic Companies Source: Generics Bulletin 10 June 2011

22. Hale & Tempest India Field Force Sizes Source: JM Financials September 2011

23. Hale & Tempest Sun Sales Source: JM Financials Sep 12 2011

24. Hale & Tempest Ranbaxy Sales Source: JM Financials 12 Sep 2011

25. Hale & Tempest Cipla Sales Source: Normura, Company data

26. Hale & Tempest DRL Sales Source: Normura, Company data

27. Hale & Tempest Lupin Sales Source: Normura, Company data

28. Hale & Tempest Branded Sales –Indian Players Source: JM Financials 12 Sep 2011

29. Hale & Tempest Generic Profit Margin Profile in descending order source: Deutsche Bank July 2010

30. Hale & Tempest Profitability Indian Players Source: JM Financials 12 Sep 2011

31. Hale & Tempest India advantages vs. USA Source: IBEF, Religare

32. Hale & Tempest India – Small Share of CRAMS Market

33. Hale & Tempest India – Small share of Global CTs Source: clinicaltrials.gov 16 Feb 2011

34. Hale & Tempest Indian CRAMs Source: Religare

35. Hale & Tempest Alexio Indian Government Coordination

36. Hale & Tempest Indian NCE Pipeline Source: Normura

37. Hale & Tempest The Indian Fear - Biosimilars

38. Hale & Tempest Biosimilars from China/India Source: New York Times 20 Sep 2011

39. Hale & Tempest Lupin - Cost of Goods (% of sales) Source: JM Financials Sep 2011

40. Hale & Tempest Generics - Rising Risk & Competition

41. Hale & Tempest European Generic Prices Source Ranbaxy

42. Hale & Tempest USA - Litigation Success Rates Source RBC Capital Markets January 15 2010  Patent Challenges on rise - 65 FTFs in 2009  Success rate at 48% - or 76% including deals  3 courts hold 69% with 36% success e.g. NJ  4 courts never ruled against generics e.g. NY  At risk launches on the rise – 6 in 2009  Teva has 12 of the 28 at risk launches – 2002/9  Settlements on the rise – 54 in 2009  Teva accounts for a third of all settlements  Authorized generics on the rise – 25 in 2009  Watson represents a fifth of all AGs

43. Hale & Tempest Season of Warning Letters/Import Alerts Source: Deutche Bank July 2011

44. Hale & Tempest Big Pharma & Generic Companies

45. Hale & Tempest A New World Order is Coming

46. Hale & Tempest Thank You brian.tempest@clara.co.uk www.briantempest.com